

Preparation of a novel radiotracer targeting the EphB4 receptor via radiofluorination using spiro azetidinium salts as precursor

Wiemer, J.; Steinbach, J.; Pietzsch, J.; Mamat, C.;

Originally published:

August 2017

Journal of Labelled Compounds and Radiopharmaceuticals 60(2017), 489-498

DOI: <https://doi.org/10.1002/jlcr.3526>

Perma-Link to Publication Repository of HZDR:

<https://www.hzdr.de/publications/Publ-25325>

Release of the secondary publication
on the basis of the German Copyright Law § 38 Section 4.

Preparation of a novel radiotracer targeting the EphB4 receptor via radiofluorination using spiro azetidinium salts as precursor

Jens Wiemer,^{a,†} Jörg Steinbach^{a,b}, Jens Pietzsch^{a,b} and Constantin Mamat^{a,b,*}

a) Institut für Radiopharmazeutische Krebsforschung, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany

b) Fachbereich Chemie und Lebensmittelchemie, Technische Universität Dresden, D-01062 Dresden, Germany

* Correspondence to: Constantin Mamat, Institut für Radiopharmazeutische Krebsforschung, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany; E-mail: c.mamat@hzdr.de

† Current address: Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany

Short title: Radiofluorinations using spiro precursors

Key words: EphB4 ligand / spiro salts / *N*-(pyrimidinyl)indazolamine

Abstract. The visualization of Eph receptors, which are overexpressed in various tumor entities, using selective small molecule Eph inhibitors by means of PET is a promising approach for tumor imaging. *N*-(Pyrimidinyl)indazolamines represent a class of compounds, which are known to have high affinity especially for the EphB4 receptor. Radiofluorination of these compounds could provide a highly specific imaging agent and was investigated using a classical nucleophilic introduction of [¹⁸F]fluoride as well as a less common nucleophilic ring opening reaction of azetidinium salts. In the past, radiofluorinations using azetidinium precursors were demonstrated to result in high radiochemical yields in short periods of time. For this purpose, an azetidinium precursor based on the *N*-(pyrimidinyl)indazolamine lead compound was developed and radiofluorination was successfully accomplished. The respective [¹⁸F]radiotracer was quickly prepared with high radiochemical purity >97% and in a radiochemical yield of 34%.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jlcr.3526

Introduction.

Aliphatic radiofluorinations commonly involve the nucleophilic introduction of [^{18}F]fluoride into alkyl compounds containing suitable leaving groups. To this end, there are two main, well-established methods for the synthesis of the resulting tertiary [^{18}F]fluoroethylamines and [^{18}F]fluoropropylamines as illustrated in Figure 1. The first method consists of preparing a [^{18}F]fluoropropyl or ethyl moiety (e.g. 1-bromo-3-[^{18}F]fluoropropane or 2-[^{18}F]fluoroethyl tosylate)¹ and subsequent introduction of this building block into secondary amine precursors using a nucleophilic displacement reaction. This two-step reaction results in overall RCYs ranging from 10 to 51%.^{2,3,4,5,6,7} In the second strategy, a tertiary amine with a propyl residue, furnished with a good leaving group at the terminal carbon atom, is directly reacted with [^{18}F]fluoride. The use of tosylate or mesylate as leaving groups is preferred, leading to RCYs ranging from 33–70%.^{2,8,9,10,11,12,13,14} A RCY of 88% was reported when using bromine as the leaving group.¹⁵

A third approach, rarely used in the past, consists of the application of aziridinium (three membered rings) and azetidinium (four membered rings) salts as precursors (Figure 1). The reactions of nucleophiles with aziridinium ions caused by ring opening of substituted heterocycles is reported to be facile¹⁶ especially for the introduction of fluorine-18.^{17,18,19} However, only little is known about ring opening reactions using azetidinium salts. It is known that these reactions lead to unbranched propyl chains when the heterocycle is unsubstituted^{20,21,22} with yields of 57–68%.

The introduction of fluorine-18 via azetidinium mesylates was first investigated by Kiesewetter and Eckelman in 2004 with RCYs for the ^{18}F -containing compounds ranging from 56–75% using n.c.a [^{18}F]fluoride.²³ Furthermore, azetidinium salts were used to successfully label molecules, which are part of pyrido[2,3-*d*]pyrimidine-scaffold, with fluorine-18 in high RCYs (81-90%)²⁴ As Pyrido[2,3-*d*]pyrimidines are known as cyclin-dependent kinase (CDK) inhibitors. Finally, two radiofluorinated bioorthogonal building blocks 1-(2-azidoethyl)-4-(2-[^{18}F]fluoroethyl)piperazine ([^{18}F]AFP) and 1-(but-3-yn-1-yl)-4-(2-[^{18}F]fluoroethyl)piperazine ([^{18}F]BFP) were prepared (RCYs 29 and 31%, d.c.)²⁵ for mild radiolabeling via the Cu-catalyzed and strain-promoted click reaction as well as both variants of the Staudinger Ligation in the case of [^{18}F]AFP.

The advantages of azetidinium salts as precursor are a convenient preparation from the open-chained compound, milder reaction conditions and a fast reaction. The strained four-membered ring, two sites for the nucleophilic attack of the [^{18}F]fluoride and the ammonium residue as good leaving group enable a quick reaction time.

Our aim consisted of the development of a new radiolabeling procedure for a fluorine-18-containing radiotracer using azetidinium salts based on inhibitor molecules for the EphB4 receptor, because EphB4 with its preferential ligand, ephrinB2, also from a radiopharmacologist's point of view is one of the most important Eph receptors.²⁶ Pro-tumorigenic effects of EphB4 activation have been described for prostate cancer²⁷ and breast cancer, whereas EphB4 knockdown resulted in reduced tumor growth in mice.²⁸ Inconsistent outcome of EphB4/ephrinB2 signalling is also described for tumorigenesis. Anti-tumorigenic effects of activated EphB4 in mouse melanoma and breast cancer cells were observed, and reduction or loss of EphB4 expression in human colorectal tumors and invasive breast carcinoma.^{29,30,31}

Several potent Eph kinase inhibitors were reported either based on high molecular weight compounds like peptides,^{32,33} which block the extracellular domain of the appropriate

receptor or based on small organic molecules^{34,35,36} which bind to the intramolecular ATP binding pocket. To date, mainly peptide-based radiotracers containing Cu-64, In-111 or F-18 are known for multimodal imaging purposes using PET or SPECT which are specific for Eph receptors.^{37,38,39}

Due to their favorable chemical and biological properties, small organic inhibitors (e.g. **I** or **III**) published by Bardelle *et al.* are the basis of our research.^{40,41,42,43} Recently, the novel fluorine-18-containing radiotracer **II** based on the benzodioxolylpyrimidine structural motif was developed and analyzed via *in vitro* and *in vivo* studies.⁴⁴ Unfortunately, despite the high affinity of the original inhibitor **I** to the EphB4 receptor ($IC_{50} = 90$ nM, recombinant EphB4), the tracer **II** showed only a moderate uptake in tumor cells (A375) and no uptake *in vivo* in the respective tumor (A375) bearing mice. This can partially be explained due to its unfavorable (bio)chemical properties like a high lipophilicity ($\log P = 3.77$). To overcome these problems, a novel lead structure was chosen based on a *N*-(pyrimidinyl)indazolumine core containing inhibitor **III** with an excellent affinity to the Eph receptor ($IC_{50} = 1.3$ nM)⁴² and practical physicochemical properties like a $\log P = 2.98$.

For this purpose, we have chosen compound **III** as basis published by Bardelle *et al.* in 2010.⁴² Previous *in silico* studies were accomplished to find the best labeling positions (structures **IV**, **V**, and **VI** in Figure 2).⁴⁵ Based on these findings, we tried to prepare an ¹⁸F-labeled compound **V** by replacing the methyl group of the original compound **III**, but without success. According to the *in silico* studies, compound **VI** should have comparable affinity. Thus, we aimed to prepare the radiotracer according this structure and to use azetidinium salts as precursor.

Results and Discussion.

Synthesis. The original compound, the resulting ¹⁸F-tracer and its precursor consists of two molecules parts as shown in Figure 3. The first part of the inhibitor (part A) was synthesized as previously described.⁴⁵ The second structure (part B) was synthesized from 4-(3-iodo-5-nitrophenyl)morpholine (**1**) which was reacted with *N*-Boc-piperazine in a Buchwald-Hartwig reaction with xantphos and Pd₂dba₃. The cross-coupled product **2** was obtained in 71% yield. Afterwards, the protecting group was removed quantitatively, leading to **3** which was then reacted with either 1-fluoro-3-iodopropane leading to **4** (80% yield) or 3-bromopropanol leading to **5** (69% yield). Next, the nitro groups in **2**, **4**, and **5** were reduced yielding anilines **6-8** (95%, 78% and 100% yields, respectively). The complete pathway to anilines **6-8** is shown in Scheme 1.

Finally, both parts A and B were connected. Thus, anilines **7** and **8** were reacted with **9** to give the EOE-protected reference compound **10** (62% yield) and the hydroxyl compound **11** (29% yield). The EOE group of **10** was cleaved under acidic conditions using 1 M HCl to give the final reference compound **14**.

To prepare the precursor, compound **11** was first treated with *p*-TsCl but no suitable product was isolable. Then, compound **11** was treated with MsCl to give the open chained compound **12**. After purification, **12** was dissolved in different solvents (dichloromethane, chloroform, acetonitrile) and warmed to prepare the final azetidinium precursor **13**. The progress of the reaction was monitored by ¹H NMR. For example, the signal for the mesyl group in **12** was found at $\delta = 3.01$ ppm whereas the same signal for the mesylate of azetidinium salt **13** was found at $\delta = 2.76$ ppm. The whole synthesis pathway is pointed out in Scheme 2.

Radiolabeling. Both precursors **12** and **13** were used for the radiolabeling. However under the used labeling conditions, **12** converted into **13**; no differences between **12** and **13** were found. Previously published conditions were used: K[¹⁸F]F, K₂CO₃, K₂₂₂, anhydrous acetonitrile to give [¹⁸F]**10** (*t_R* = 30.7 min).⁴⁵ For the removal of the EOE group, [¹⁸F]**10** was treated with 2 M HCl to yield [¹⁸F]**14** (*t_R* = 11.9 min) (Scheme 3/Figure 3). After deprotection, a spot at *R_f* = 0.37 (solvent: dichloromethane/methanol = 9/1) belonging to the final ¹⁸F-tracer [¹⁸F]**14** was determined by comparison with the non-radioactive compound **13** using radio-TLC analyses (Figure 4). Purification was done using semi-preparative HPLC yielding [¹⁸F]**14** in 34% RCY.

logP determination. The lipophilicities of the original inhibitor **III** and the fluorine-containing compound **14** were determined according to the shake flask method reported elsewhere.⁴⁶ A logP value of 2.98 was determined for the original inhibitor **III** and a value of 2.55 for compound **14**. Both compounds seemed to be more hydrophilic compared to the previous prepared radiotracers. The results are summarized in Table 1.

Conclusion. In this short note, we have demonstrated the successful radiolabeling of a radiotracer based on the *N*-(pyrimidinyl)indazolamine core structure suitable for the visualization of the EphB4 receptor. [¹⁸F]**14** was prepared via a nucleophilic ring opening reaction of the appropriate azetidinium salt precursor **13** in a RCY of 34% after cleavage of the EOE protecting group. The precursor **13** was formed from the respective open-chained mesyl compound **12**. Further analyses were accomplished showing an improved lipophilicity with a logP of 2.55 compared to the recently published tracer **II**. Biological and radiobiological studies are in progress and will be reported separately.

Experimental

Materials and Methods

All reagents were purchased from commercial suppliers and used without further purification. Compounds **1** and **9** were prepared according to the literature. Analytical TLC was performed on pre-coated Silica Gel 60 F₂₅₄ plates (Merck) and the results visualized under UV-light ($\lambda = 254$ nm). ¹H NMR, ¹³C NMR and ¹⁹F NMR spectra were recorded on a Varian Inova-400 or Agilent DD2-400 (OneNMR Probe) spectrometer at 400, 101, and 376 MHz, respectively. Chemical shifts are reported in ppm with tetramethylsilane (¹H, ¹³C) and trichlorofluoromethane (¹⁹F) as internal standard, respectively. MS spectra were obtained on a Xevo TQ-S (Waters) by electron spray (ESI) as the ionization method. Melting points were determined using a Cambridge Instruments Galen III apparatus and are uncorrected. Analytical HPLC was performed on a VWR/Hitachi Elite La Chrome HPLC system, equipped with a reverse phase column (Nucleosil 100-5C18 Nautilus), a UV-diode array detector (254 nm) and a scintillation radiodetector (Raytest, Gabi Star) at a flow rate of 1 mL/min (eluent: acetonitrile/water, 20:80 + 0.1% TFA, isocratic). The radioactive compound was identified with analytical radio-HPLC by comparison of the retention time of the reference compound. Decay-corrected RCYs were quantified by integration of radioactive peaks on a radio-TLC using a radio-TLC scanner (Fuji, BAS2000). [¹⁸F]Fluoride was produced by the ¹⁸O(*p,n*)¹⁸F nuclear reaction utilizing the PET cyclotron Cyclone 18/9 (IBA, Belgium); [¹⁸O]H₂O was irradiated.

tert-Butyl 4-(3-morpholino-5-nitrophenyl)piperazine-1-carboxylate **2**

Compound **1** (600 mg, 1.80 mmol) was dissolved in anhydrous toluene (15 mL) in a Schlenk tube under argon atmosphere. 1-Boc-piperazine (672 mg, 3.60 mmol) and Cs₂CO₃ (2.93 g, 8.99 mmol) were added. Pd₂dba₃ and xantphos were added in catalytic amounts. The mixture was stirred at 90 °C for 24 h. After cooling to rt, the reaction was quenched with H₂O (15 mL) and extracted with EtOAc (3 x 15 mL). The organic layer was dried over Na₂SO₄ and concentrated under reduced pressure and the crude product was purified by flash column chromatography (PE–EtOAc = 2:1 → 1:1) to yield compound **2** (634 mg, 90%) as an orange solid. Mp. 202 °C; *R*_f = 0.66 (PE–EtOAc = 1:1); ¹H NMR: (400 MHz, CDCl₃): δ = 1.49 (9H, s, CH₃), 3.18–3.24 (8H, m, CH₂N), 3.59 (4H, t, ³*J* = 5.1, CH₂N), 3.87 (4H, t, ³*J* = 4.9, CH₂O), 6.64 (1H, t, ⁴*J* = 2.1, 2-H), 7.26 (2H, d, ⁴*J* = 2.1 Hz, 4/6-H); ¹³C NMR (101 MHz, CDCl₃): δ = 28.6 (CH₃), 49.1 (CH₂N), 66.8 (CH₂O), 80.3 (C_q), 102.2, 102.7 (C-4/6), 108.6 (C-2), 150.3 (C-1), 152.7, 152.8 (C-3/5), 154.8 (C=O); MS (ESI⁺): *m/z* 415 (49) [M⁺+Na], 393 (100) [M⁺+H]; elemental analysis calcd. for C₁₉H₂₈N₄O₅ (392.45): C, 58.15, H, 7.19, N, 14.28; found: C, 58.44, H, 7.50, N, 14.42%.

4-(3-Nitro-5-(piperazin-1-yl)phenyl)morpholine **3**

Compound **2** (1.85 g, 4.71 mmol) was dissolved in anhydrous dichloromethane (40 mL), trifluoroacetic acid (4 mL) was added dropwise and the mixture was stirred overnight at rt. After the removal of the solvent, 50 mL of a 10% K₂CO₃ solution was added and the aqueous layer extracted with dichloromethane (3 x 15 mL). The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure to yield compound **3** (1.36 g, 99%) as an orange solid without further purification. Mp 144 °C; *R*_f = 0.17 (CHCl₃–MeOH = 9:1); ¹H NMR: (400 MHz, CDCl₃): δ = 1.68 (1H, br. s, NH), 3.04 (4H, t, ³*J* = 4.9, CH₂N), 3.21 (8H, t, ³*J* = 4.9, CH₂N), 3.87 (4H, t, ³*J* = 4.9, CH₂O), 6.65 (1H, t, ⁴*J* = 2.1, 6-H), 7.23 (1H, t, ⁴*J* = 2.0, H_{Af}), 7.27 (1H, t, ⁴*J* = 2.0, H_{Ar}); ¹³C NMR (101 MHz, CDCl₃): δ = 46.1, 49.2, 50.1 (3 x CH₂N), 66.8 (CH₂O), 101.7, 102.4 (C-4/6), 108.1 (C-2), 150.3 (C-1), 152.7, 153.1 (C-3/5); MS (ESI⁺): *m/z* 293 (100) [M⁺+H]; elemental calcd. for C₁₄H₂₀N₄O₃ (292.33): C, 57.52, H, 6.90, N, 19.17; found: C, 57.36, H, 6.94, N, 19.04%.

4-(3-(4-(3-Fluoropropyl)piperazin-1-yl)-5-nitrophenyl)morpholine **4**

Compound **3** (500 mg, 2.57 mmol), 1-fluoro-3-iodopropane (482 mg, 2.57 mmol) and Et₃N (346 mg, 3.42 mmol) were dissolved in anhydrous THF (20 mL) and the reaction mixture was stirred at 60 °C overnight. The

reaction was quenched with H₂O (30 mL), extracted with dichloromethane (3 x 20 mL), the organic layer was dried over Na₂SO₄ and the solvent removed. Purification was performed by flash chromatography (CHCl₃–MeOH = 20:1) to yield compound **4** as an orange solid (479 mg, 80%). Mp 102 °C; *R*_f = 0.82 (CHCl₃–MeOH = 10:1); ¹H NMR: (400 MHz, CDCl₃): δ = 1.85–2.00 (2H, m, CH₂CH₂F), 2.55 (2H, t, ³*J* = 7.4, CH₂N), 2.62 (4H, t, ³*J* = 4.8, CH₂N), 3.21 (4H, t, ³*J* = 5.0, CH₂N), 3.25 (4H, t, ³*J* = 5.0, CH₂N), 3.86 (4H, t, ³*J* = 5.0, CH₂O), 4.54 (2H, dt, ²*J*_{H,F} = 47.2, ³*J* = 5.9, CH₂F), 6.65 (1H, t, ⁴*J* = 2.1, 2-H), 7.23 (1H, t, ⁴*J* = 1.9, H_{Ar}), 7.27 (1H, t, ⁴*J* = 2.0, H_{Ar}); ¹³C NMR (101 MHz, CDCl₃): δ = 28.1 (d, ²*J*_{C,F} = 19.4, CH₂CH₂F), 48.9, 49.2, 53.1 (3 x CH₂N), 54.3 (d, ⁴*J*_{C,F} = 5.3, CH₂N), 66.8 (CH₂O), 82.5 (d, ¹*J*_{C,F} = 165.1, CH₂CH₂F), 101.7, 102.4 (C-6/4), 108.0 (C-2), 150.3 (C-5), 152.6, 152.7 (C-1/3); ¹⁹F NMR (376 MHz, CDCl₃): δ = –220.6; MS (ESI⁺): *m/z* 352 (100) [M⁺+H]; elemental calcd. for C₁₇H₂₅FN₄O₃ (352.40): C, 57.94, H, 7.15, N, 15.90; found: C, 57.76, H, 7.08, N, 15.35.

3-(4-(3-Morpholino-5-nitrophenyl)piperazin-1-yl)propan-1-ol **5**

Compound **3** (500 mg, 1.71 mmol), 3-bromopropan-1-ol (380 mg, 2.73 mmol) and Et₃N (0.38 mL, 2.73 mmol) were dissolved in anhydrous THF (15 mL), NaI (50 mg) was added and the reaction mixture was stirred at 60 °C overnight. The mixture was treated with H₂O (20 mL), extracted with dichloromethane (3 x 20 mL), the organic layer was dried over Na₂SO₄ and the solvent removed. Purification was performed by flash chromatography (CHCl₃–MeOH = 10:1) to yield compound **5** as an orange solid (530 mg, 88 %). Mp 128 °C, *R*_f = 0.53 (CHCl₃–MeOH = 9:1); ¹H NMR: (400 MHz, CDCl₃): δ = 1.78 (2H, qi, ³*J* = 5.6, CH₂CH₂OH), 2.65–2.72 (6H, m, 3 x CH₂N), 3.21 (4H, t, ³*J* = 4.8, CH₂N), 3.26 (4H, t, ³*J* = 5.0, CH₂N), 3.83 (2H, t, ³*J* = 5.3, CH₂OH), 3.86 (4H, t, ³*J* = 4.8, CH₂O), 6.63 (1H, t, ⁴*J* = 2.1, 2-H), 7.23 (1H, t, ⁴*J* = 2.0, H_{Ar}), 7.26 (1H, t, ⁴*J* = 2.0, H_{Ar}). ¹³C NMR (101 MHz, CDCl₃): δ = 27.3 (CH₂CH₂O), 48.9, 49.1, 53.2, 58.7 (4 x CH₂N), 64.5, 66.8 (2 x CH₂O), 101.9, 102.6 (C-6/4), 108.1 (C-2), 150.3 (C-5), 152.5, 152.7 (C-1/3); MS (ESI⁺): *m/z* 351 (100, M⁺+H); elemental calcd. for C₁₇H₂₆N₄O₄ (350.41): C, 58.27, H, 7.48, N, 15.99; found C, 58.06, H, 7.51, N, 16.13.

3-(4-*tert*-Butoxycarbonyl)piperazino-5-morpholinoaniline **6**

Compound **2** (930 mg, 2.37 mmol) was dissolved in CHCl₃/MeOH (20 mL, v:v = 1:1) and Pd/C (500 mg) was added. The resulting mixture was treated with H₂ (approx. 1 bar) at rt for 24 h. Afterwards, the catalyst was filtered and washed with CHCl₃ (10 mL). The solvent of the combined filtrates was removed under reduced pressure to yield compound **6** (819 mg, 95%) as colorless solid. Mp 173 °C; *R*_f = 0.06 (PE–EtOAc = 1:1); ¹H NMR: (400 MHz, CDCl₃): δ = 1.47 (9H, s, CH₃), 3.07–3.12 (8H, m, CH₂N), 3.54 (4H, t, ³*J* = 5.2, CH₂N), 3.82 (4H, t, ³*J* = 4.9, CH₂O), 5.84 (2H, d, ⁴*J* = 1.7, 2/6-H), 5.93 (1H, t, ⁴*J* = 1.7, 4-H); ¹³C NMR (101 MHz, CDCl₃): δ = 28.6 (CH), 49.7, 49.8 (2 x CH₂N), 67.1 (CH₂O), 80.0 (C_q), 96.0, 96.2 (C-2/4), 96.6 (C-6), 148.1 (C-3), 153.5, 153.6 (C-1/5), 154.9 (C=O); MS (ESI⁺): *m/z* 363 (100, M⁺+H); elemental calcd. for C₁₉H₃₀N₄O₃ (362.47): C, 62.96, H 8.34, N, 15.46; found: C, 63.07, H, 8.40, N, 15.38%.

3-(4-(3-Fluoropropyl)piperazin-1-yl)-5-morpholinoaniline **7**

Compound **4** (479 mg, 1.49 mmol) was dissolved in MeOH (50 mL) and Pd/C (150 mg) was added. The resulting mixture was treated with H₂ (approx. 1 bar) at rt for 24 h. Afterwards, the catalyst was filtered and washed with CHCl₃ (10 mL). The solvent of the combined filtrates was removed under reduced pressure to yield compound **7** (438 mg, 100%) as brown syrup. *R*_f = 0.37 (CHCl₃–MeOH = 10:1); ¹H NMR: (400 MHz, CDCl₃): δ = 1.83–1.99 (2H, m, CH₂CH₂F), 2.52 (2H, t, ³*J* = 7.4, CH₂N), 2.58 (4H, t, ³*J* = 5.0, CH₂N), 3.10 (4H, t, ³*J* = 4.8, CH₂N), 3.15 (4H, t, ³*J* = 5.1, CH₂N), 3.82 (4H, t, ³*J* = 4.8, CH₂O), 4.52 (2H, dt, ²*J*_{H,F} = 47.1, ³*J* = 6.0, CH₂F), 5.81 (1H, t, ⁴*J* = 1.9, H_{Ar}), 5.85 (1H, t, ⁴*J* = 1.9, H_{Ar}), 5.93 (1H, t, ⁴*J* = 1.9, H_{Ar}); ¹³C NMR (101 MHz, CDCl₃): δ = 28.0 (d, ²*J*_{C,F} = 19.7, CH₂CH₂F), 49.4, 49.8, 53.4 (3 x CH₂N), 54.4 (d, ⁴*J*_{C,F} = 5.5, CH₂N), 67.1 (CH₂O), 82.6 (d, ¹*J*_{C,F} = 164.4, CH₂CH₂F), 95.6, 95.8, 96.2 (3 x Ar-CH), 148.0, 153.4, 153.5 (3 x Ar-C_q); ¹⁹F NMR (376 MHz, CDCl₃): δ = –220.4; MS (ESI⁺): *m/z* 345 (9, M⁺+Na), 323 (46, M⁺+H); elemental calcd. for C₁₇H₂₇FN₄O (322.42): C, 63.33, H, 8.44, N, 17.38; found: C, 63.03, H, 8.41, N, 17.44.

3-(4-(3-Amino-5-morpholinophenyl)piperazin-1-yl)propan-1-ol **8**

Compound **5** (1.10 g, 3.14 mmol) was dissolved in CHCl₃ (20 mL) and Pd/C (200 mg) was added. The resulting mixture was treated with H₂ (approx. 1 bar) at rt for 24 h. Afterwards, the catalyst was filtered and washed with CHCl₃ (10 mL). The solvent of the combined filtrates was removed under reduced pressure to yield compound **8** (887 mg, 88%) as light brown syrup. *R*_f = 0.22 (CHCl₃–MeOH = 10:1); ¹H NMR: (400 MHz, CDCl₃): δ = 1.80 (2H, qi, ³*J* = 5.2, CH₂CH₂OH), 2.70–2.80 (6H, m, 3 x CH₂N), 3.10 (4H, t, ³*J* = 4.8, CH₂N), 3.21 (4H, t, ³*J* = 4.8, CH₂N), 3.79–3.86 (6H, m, CH₂O/CH₂OH), 5.84 (2H, d, ⁴*J* = 2.0, 2-/5-H), 5.92 (1H, t, ⁴*J* = 2.0, 4-H). ¹³C NMR (101 MHz, CDCl₃): δ = 27.2 (CH₂CH₂O), 49.5, 49.8, 53.5, 58.9 (4 x CH₂N), 64.5, 67.1 (2 x CH₂O), 95.9, 96.0,

96.4 (3 x Ar-CH), 148.1, 153.3, 153.5 (3 x Ar-C_q). MS (ESI⁺): *m/z* 321 (100, M⁺+H); elemental calcd. for C₁₇H₂₈N₄O₂ (320.43): C, 63.72, H, 8.81, N, 17.48; found: C, 63.88, H, 8.66, N, 17.28.

*N*²-(3-(4-(3-Fluoropropyl)piperazin-1-yl)-5-morpholinophenyl)-*N*⁴-(1-(1-ethoxyethyl)-1*H*-indazol-4-yl)-*N*⁴-methylpyrimidin-2,4-diamine **10**

Compound **7** (358 mg, 1.11 mmol) and compound **9** (405 mg, 1.22 mmol) were dissolved in anhydrous dioxane (10 mL), *p*-TsOH·H₂O was added in catalytic amounts and the resulting mixture was stirred at 90°C for 24 h. After cooling to rt, saturated hydrogencarbonate solution was added (30 mL), the aqueous layer was extracted with EtOAc (3 x 20 mL), the combined organic layers were dried over Na₂SO₄ and the solvent was removed. Purification was performed by flash chromatography (CHCl₃-MeOH = 25:1) to yield compound **10** as a brownish solid (428 mg, 62%). *R*_f = 0.63 (CHCl₃-MeOH = 4:1); ¹H NMR: (400 MHz, CDCl₃): δ = 7.82 (d, ⁵*J*_{3,5} = 0.7 Hz, 1H, H-3), 7.80 (d, ³*J*_{6',5'} = 6.0 Hz, 1H, H-6'), 7.68 (d, ³*J*_{7,6} = 8.6 Hz, 1H, H-7), 7.42 (dd, ³*J*_{6,5} = 7.4, ³*J*_{6,7} = 8.6 Hz, 1H, H-6), 7.07 (dd, ³*J*_{5,6} = 7.4 Hz, ⁵*J*_{5,3} = 0.7 Hz, 1H, H-5), 6.97 (s, 1H, NH), 6.90 - 6.88 (m, 2H, H-2''/6''), 6.19 (t, ⁴*J*_{4'',2''} = ⁴*J*_{4'',6''} = 2.0 Hz, 1H, H-4''), 5.91 (q, ³*J* = 6.1 Hz, 1H, CH), 5.71 (d, ³*J*_{5',6'} = 6.0 Hz, 1H, H-5'), 4.53 (dt, ³*J* = 5.9 Hz; ²*J*_{H,F} = 47.3 Hz, 2H, CH₂F), 3.85 (t, ³*J* = 4.9 Hz, 4H, CH₂N), 3.63 (s, 3H, CH₃), 3.49 (dq, ²*J* = 9.3 Hz, ³*J* = 7.1 Hz, 1H, CH₂CH₃), 3.32 (dq, ²*J* = 9.3 Hz, ³*J* = 7.1 Hz, 1H, CH₂CH₃), 3.23 (t, ³*J* = 4.9 Hz, 4H, CH₂N), 3.17 (t, ³*J* = 4.9 Hz, 4H, CH₂N), 2.61 (t, ³*J* = 4.9 Hz, 4H, CH₂N), 2.53 (t, ³*J* = 7.4 Hz, 2H, CH₂N), 1.99 - 1.86 (m, 2H, CH₂CH₂CH₂), 1.82 (d, ³*J* = 6.1 Hz, 3H, CHCH₃), 1.17 (t, ³*J* = 7.1 Hz, 3H, CH₂CH₃). ¹³C NMR (101 MHz, CDCl₃): δ = 163.0 (C-4'), 159.8 (C-2'), 155.8 (C-6'), 152.9, 152.6 (C-3''/-5''), 140.8 (C-7a) 140.1 (C-4), 136.8 (C-1''), 131.2 (C-3), 127.4 (C-6), 122.1 (C-3a), 119.4 (C-5), 110.6 (C-5'), 100.8 (C-7), 100.3 (C-4''), 99.8, 97.3 (C-2''/-6''), 87.6 (CH), 82.4 (d, ¹*J*_{C,F} = 164.5 Hz, CH₂F), 67.1 (CH₂O), 64.1 (CH₂), 54.5 (d, ³*J*_{C,F} = 5.4 Hz, CH₂N), 53.3, 49.9, 49.4 (3 x CH₂N), 38.6 (CH₃), 27.7 (d, ²*J*_{C,F} = 18.8 Hz, CH₂CH₂F) 21.1, 15.0 (2 x CH₃). ¹⁹F NMR (376 MHz, CDCl₃): δ = -220.2. MS (ESI⁺): *m/z* (%) = 618 (30) [M⁺+H], 546 (100) [M⁺+H-EOE].

*N*²-(3-(4-(3-Hydroxypropyl)piperazin-1-yl)-5-morpholinophenyl)-*N*⁴-(1-(1-ethoxyethyl)-1*H*-indazol-4-yl)-*N*⁴-methylpyrimidin-2,4-diamine **11**

Compound **8** (159 mg, 0.50 mmol) and compound **9** (181 mg, 0.55 mmol) were dissolved in anhydrous dioxane (7 mL), *p*-TsOH·H₂O was added in catalytic amounts and the resulting mixture was stirred at 90°C for 24 h. After cooling to rt, saturated hydrogencarbonate solution was added (20 mL), the aqueous layer was extracted with EtOAc (3 x 15 mL), the combined organic layers were dried over Na₂SO₄ and the solvent was removed. Purification was performed by flash chromatography (CHCl₃-MeOH = 20:1→10:1) to yield compound **11** as a brownish oil (90 mg, 29%). *R*_f = 0.52 (CHCl₃-MeOH = 4:1); ¹H NMR (400 MHz, CDCl₃): δ = 7.81 (d, ⁵*J*_{3,5} = 0.7 Hz, 1H, H-3), 7.79 (d, ³*J*_{6',5'} = 6.0 Hz, 1H, H-6'), 7.68 (d, ³*J*_{7,6} = 8.6 Hz, 1H, H-7), 7.41 (t, ³*J*_{6,5} = 7.4 Hz, ³*J*_{6,7} = 8.6 Hz, 1H, H-6), 7.20 (s, 1H, NH), 7.07 (dd, ³*J*_{5,6} = 7.4 Hz, ⁵*J*_{5,3} = 0.7 Hz, 1H, H-5), 6.91 (t, ³*J* = 2.0 Hz, 1H, HAr), 6.88 (t, ³*J* = 2.0 Hz, 1H, HAr), 6.17 (t, ⁴*J*_{4'',2''} = ⁴*J*_{4'',6''} = 2.0 Hz, 1H, H-4''), 5.91 (q, ³*J* = 6.1 Hz, 1H, CH), 5.71 (d, ³*J*_{5',6'} = 6.0 Hz, 1H, H-5'), 3.85 - 3.80 (m, 6H, CH₂O, CH₂OH), 3.62 (s, 3H, CH₃), 3.49 (dq, ²*J* = 9.3 Hz, ³*J* = 7.1 Hz, 1H, CH₂CH₃), 3.31 (dq, ²*J* = 9.3 Hz, ³*J* = 7.1 Hz, 1H, CH₂CH₃), 3.22 (t, ³*J* = 5.0 Hz, 4H, CH₂N), 3.16 (t, ³*J* = 4.8 Hz, 4H, CH₂N), 2.69-2.66 (m, 6H, CH₂N), 1.82 (d, ³*J* = 6.1 Hz, 3H, CHCH₃), 1.78 - 1.73 (m, 2H, CH₂CH₂CH₂), 1.17 (t, ³*J* = 7.1 Hz, 3H, CH₂CH₃). ¹³C NMR (101 MHz, CDCl₃): δ = 162.9 (C-4'), 159.5 (C-2'), 155.1 (C-6'), 152.9, 152.7 (C-3''/-5''), 150.5 (C-1''), 141.6 (C-7a) 140.1 (C-4), 131.6 (C-3), 127.4 (C-6), 122.3 (C-3a), 119.4 (C-5), 110.0 (C-5'), 100.4 (C-7), 100.0 (C-4''), 99.3, 97.5 (C-2''/-6''), 87.4 (CH), 67.1, 64.5 (2 x CH₂O), 64.0 (CH₂), 58.9, 53.5, 50.0, 49.7 (4 x CH₂N), 38.3 (CH₃), 27.2 (CH₂CH₂CH₂), 21.1, 15.0 (2 x CH₃). MS (ESI⁺): *m/z* (%) = 616 (40) [M⁺+H], 544 (100) [M⁺-EOE].

*N*²-(3-(4-(3-Fluoropropyl)piperazin-1-yl)-5-morpholinophenyl)-*N*⁴-(1*H*-indazol-4-yl)-*N*⁴-methylpyrimidin-2,4-diamine **14**

Compound **10** (384 mg, 0.62 mmol) was treated with HCl (12 mL, 1 M) and stirred at rt for 1.5 h. Afterwards, a saturated hydrogencarbonate solution was added for neutralization, the aqueous layer was extracted with chloroform (3 x 20 mL), the combined organic layers were dried over Na₂SO₄ and the solvent was removed. Purification was performed by flash chromatography (CHCl₃-MeOH = 30:1) to yield compound **14** as a brownish oil (288 mg, 85%). *R*_f = 0.35 (CHCl₃-MeOH = 9:1); ¹H NMR: (400 MHz, CDCl₃): δ = 10.56 (s, 1H, NH), 7.91 (d, ⁵*J*_{3,5} = 0.8 Hz, 1H, H-3), 7.81 (d, ³*J*_{6',5'} = 6.0 Hz, 1H, H-6'), 7.46 - 7.41 (m, 2H, H-6/-7), 7.10 (s, 1H, NH), 7.08 (dd, ³*J*_{5,6} = 6.5 Hz, ⁵*J*_{5,3} = 0.8 Hz, 1H, H-5), 6.90 - 6.88 (m, 2H, H-2''/6''), 6.19 (t, ⁴*J*_{4'',2''} = ⁴*J*_{4'',6''} = 2.0 Hz, 1H, H-4''), 5.91 (q, ³*J* = 6.1 Hz, 1H, CH), 5.71 (d, ³*J*_{5',6'} = 6.0 Hz, 1H, H-5'), 4.53 (dt, ³*J* = 5.9 Hz; ²*J*_{H,F} = 47.3 Hz, 2H, CH₂F), 3.85 (t, ³*J* = 4.9 Hz, 4H, CH₂N), 3.63 (s, 3H, CH₃), 3.49 (dq, ²*J* = 9.3 Hz, ³*J* = 7.1 Hz, 1H, CH₂CH₃), 3.32 (dq, ²*J* = 9.3 Hz, ³*J* = 7.1 Hz, 1H, CH₂CH₃), 3.23 (t, ³*J* = 4.9 Hz, 4H, CH₂N), 3.17 (t, ³*J* = 4.9 Hz, 4H, CH₂N), 2.61 (t, ³*J* = 4.9 Hz, 4H, CH₂N), 2.53 (t, ³*J* = 7.4 Hz, 2H, CH₂N), 1.99 - 1.86 (m, 2H, CH₂CH₂CH₂), 1.82 (d, ³*J* = 6.1 Hz, 3H, CHCH₃), 1.17 (t, ³*J* = 7.1 Hz, 3H, CH₂CH₃). ¹³C NMR (101 MHz, CDCl₃): δ = 163.0 (C-4'), 159.8 (C-2'), 155.8 (C-6'), 152.9, 152.6 (C-3''/-5''), 140.8 (C-7a) 140.1 (C-4), 136.8 (C-1''), 131.2 (C-3), 127.4 (C-6), 122.1 (C-3a), 119.4 (C-5), 110.6 (C-5'), 100.8 (C-7), 100.3 (C-4''), 99.8, 97.3 (C-2''/-6''), 87.6 (CH), 82.4 (d, ¹*J*_{C,F} = 164.5 Hz, CH₂F), 67.1 (CH₂O), 64.1 (CH₂), 54.5 (d, ³*J*_{C,F} = 5.4 Hz, CH₂N), 53.3, 49.9, 49.4 (3 x CH₂N), 38.6 (CH₃), 27.7 (d, ²*J*_{C,F} = 18.8 Hz, CH₂CH₂F) 21.1, 15.0 (2 x CH₃). ¹⁹F NMR (376 MHz, CDCl₃): δ = -220.2. MS (ESI⁺): *m/z* (%) = 618 (30) [M⁺+H], 546 (100) [M⁺+H-EOE].

= 2.1 Hz, 1H, H-4"), 5.71 (d, $^3J_{5,6'} = 6.0$ Hz, 1H, H-5'), 4.53 (dt, $^3J = 6.0$ Hz; $^2J_{\text{H,F}} = 47.3$ Hz, 2H, CH₂F), 3.85 (t, $^3J = 4.8$ Hz, 4H, CH₂O), 3.63 (s, 3H, CH₃), 3.22 (t, $^3J = 4.8$ Hz, 4H, CH₂N), 3.16 (t, $^3J = 4.8$ Hz, 4H, CH₂N), 2.61 (t, $^3J = 4.8$ Hz, 4H, CH₂N), 2.54 (t, $^3J = 7.4$ Hz, 2H, CH₂N), 1.99 - 1.86 (m, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃): δ = 163.0 (C-4'), 159.9 (C-2'), 155.7 (C-6'), 152.9, 152.9 (C-3''/-5''), 141.8 (C-7a) 141.7 (C-4), 137.5 (C-1'), 133.2 (C-3), 127.8 (C-6), 120.7 (C-3a), 119.3 (C-5), 109.1 (C-5'), 100.2 (C-7), 99.7 (C-4''), 99.1, 97.4 (C-2''/-6''), 82.7 (d, $^1J_{\text{C,F}} = 164.5$ Hz, CH₂F), 67.2 (CH₂O), 54.5 (d, $^3J_{\text{C,F}} = 5.5$ Hz, CH₂N), 53.4, 50.0, 49.7 (3 x CH₂N), 38.3 (CH₃), 28.0 (d, $^2J_{\text{C,F}} = 19.8$ Hz, CH₂CH₂F). ¹⁹F NMR (376 MHz, CDCl₃): δ = -220.0 ppm. MS (ESI+): *m/z* (%) = 546 (100) [M⁺+H].

*N*²-(3-(4-(3-Methylsulfonyloxypropyl)piperazin-1-yl)-5-morpholinophenyl)-*N*⁴-(1-(1-ethoxyethyl)-1*H*-indazol-4-yl)-*N*⁴-methylpyrimidin-2,4-diamin **12**

Compound **11** (65 mg, 0.11 mmol) was dissolved in anhydrous dichloromethane (10 mL), MsCl (18 mg, 0.16 mmol) and DIPEA (27 mg, 0.21 mmol) were added and the resulting mixture was stirred for 1 h at rt.

Afterwards, water (10 mL) was added and the aqueous layer was extracted with dichloromethane (3 x 5 mL), the combined organic layers were dried over Na₂SO₄ and the solvent was removed at temperatures below 30°C to yield compound **12** as a light brownish oil (64 mg, 87%). *R*_f = 0.55 (CHCl₃-MeOH = 10:1); ¹H NMR: (400 MHz, CDCl₃): δ = 7.81 (d, $^5J_{3,5} = 0.8$ Hz, 1H, H-3), 7.79 (d, $^3J_{6',5'} = 6.0$ Hz, 1H, H-6'), 7.68 (d, $^3J_{7,6} = 8.5$ Hz, 1H, H-7), 7.41 ("t", $^3J_{6,7} = 8.5$ Hz, $^3J_{6,5} = 7.4$ Hz, 1H, H-6), 7.12 (s, 1H, NH), 7.07 (dd, $^3J_{5,6} = 7.4$ Hz, $^5J_{5,3} = 0.8$ Hz, 1H, H-5), 6.89 (m, 2H, H_{ar}), 6.18 (t, $^4J_{4'',2''} = ^4J_{4'',6''} = 2.0$ Hz, 1H, H-4"), 5.92 (q, $^3J = 6.1$ Hz, 1H, CH), 5.71 (d, $^3J_{5',6'} = 6.0$ Hz, 1H, H-5'), 4.32 (t, $^3J = 7.0$ Hz, 2H, CH₂N), 3.85 - 3.83 (m, 4H, CH₂O), 3.62 (s, 3H, CH₃), 3.49 (dq, $^2J = 9.3$ Hz, $^3J = 7.0$ Hz, 1H, CH₂CH₃), 3.31 (dq, $^2J = 9.3$ Hz, $^3J = 7.0$ Hz, 1H, CH₂CH₃), 3.21 (t, $^3J = 5.0$ Hz, 4H, CH₂N), 3.17 (t, $^3J = 5.0$ Hz, 4H, CH₂N), 3.01 (s, 3H, CH₃S), 2.59 (t, $^3J = 5.0$ Hz, 4H, CH₂N), 2.51 (t, $^3J = 7.0$ Hz, 2H, CH₂N), 1.99 - 1.93 (m, 2H, CH₂), 1.81 (d, $^3J = 6.1$ Hz, 3H, CHCH₃), 1.17 (t, $^3J = 7.0$ Hz, 3H, CH₂CH₃). ¹³C NMR (101 MHz, CDCl₃): δ = 162.9 (C-4'), 159.8 (C-2'), 155.7 (C-6'), 152.9, 152.8 (C-3''/-5''), 150.5 (C-1''), 141.7 (C-7a) 140.1 (C-4), 131.6 (C-3), 127.4 (C-6), 122.3 (C-3a), 119.4 (C-5), 109.9 (C-5'), 100.2 (C-7), 99.6 (C-4''), 99.0, 97.5 (C-2''/-6''), 87.4 (CH), 68.5, 67.1 (2 x CH₂O), 64.0 (CH₂), 54.1, 53.4, 50.0, 49.7 (4 x CH₂N), 38.2, 37.4 (2 x CH₃), 26.6 (CH₂), 21.1, 15.0 (2 x CH₃). MS (ESI+): *m/z* (%) = 636 (100) [M⁺+H-EOE].

*N*²-(3-(4-(3-[¹⁸F]Fluoropropyl)piperazin-1-yl)-5-morpholinophenyl)-*N*⁴-(1*H*-indazol-4-yl)-*N*⁴-methylpyrimidin-2,4-diamine [¹⁸F]**14**

An anion-exchange cartridge (Waters, Sep-Pak Light Accell Plus QMA) was activated by rinsing with 10 mL of a 1M NaHCO₃ solution and 10 mL of deionized H₂O. [¹⁸F]Fluoride was trapped on the cartridge, eluted with a Kryptofix K 2.2.2./K₂CO₃ solution (1.5 mL) into the reaction vessel and dried via azeotropic distillation with anhydrous acetonitrile (3 x 2 mL) under a stream of nitrogen at 100°C for approx. 30 min. Precursor **12** or **13** (~3 mg) was dissolved in 500 μL of anhydrous acetonitrile, and the mixture was added to the [¹⁸F]fluoride-containing sealed vial. The resulting solution was heated at 100°C for 30 min. Afterwards, HCl (100 μL / 2 M) was added and the mixture was heated at 100°C for further 5 min. Next, the mixture was treated with 15 mL deionized H₂O and then passed through a C18 cartridge (LiChrolut RP-18/Merck). After elution with ethanol, samples for analytical radio-TLC and radio-HPLC were taken. Analytical radio-TLC: *R*_f = 0.37 (dichloromethane/methanol, 9/1). Analytical radio-HPLC: *t*_R = 11.9 min (eluent: acetonitrile/water 20/80 + 0.1% TFA). Purification was done via semi-preparative radio-HPLC.

Acknowledgements. The authors thank the Fonds der Chemischen Industrie (FCI, Germany) for financial support. The authors also thank the Helmholtz Association for funding a part of this work through Helmholtz-Portfolio Topic "Technologie und Medizin – Multimodale Bildgebung zur Aufklärung des In vivo-Verhaltens von polymeren Biomaterialien". The excellent technical assistance of Waldemar Herzog is gratefully acknowledged.

Table 1. Comparison of calculated vs. determined logP values.

| compound | calcd. logP ⁴⁷ | calcd. logP ⁴⁸ | expt. logP |
|------------|---------------------------|---------------------------|------------|
| I | 3.30 | 2.77 | n.d. |
| II | 3.77 | 3.11 | n.d. |
| III | 3.42 | 3.40 | 2.98 |
| 14 | 3.87 | 3.34 | 2.55 |

Accepted Article




Figure 1. General strategies for the insertion of a [^{18}F]fluoroethyl or [^{18}F]fluoropropyl moiety.




Figure 2. Overview of original inhibitors **I** and **III** as basis for the development of possible radiotracers **IV – VI** and recently prepared [^{18}F]tracer **II**.




Figure 3. Radio-HPLC chromatogram of $[^{18}\text{F}]10$ (EOE protected) and the final tracer $[^{18}\text{F}]14$ (deprotected) after purification.

Accepted Article






Figure 4. Radio-TLC chromatogram of the final tracer [¹⁸F]14 from the reaction mixture after deprotection.

Accepted Article



Scheme 2. Synthesis pathway for precursor **13** and reference compound **14**. *Reagents and conditions:* a) *p*-TsOH, dioxane, 90°C, overnight; b) HCl, EtOH, 1.5 h; c) MsCl, DCM, rt, 60 min; d) acetonitrile, 60°C, 3 h.



Scheme 3. General radiolabeling procedure for $[^{18}\text{F}]\mathbf{14}$ from precursors **12** and **13**. Reagents and conditions: a) $\text{K}[^{18}\text{F}]\text{F}$, K_2CO_3 , K_{222} , acetonitrile, 100°C , 30 min.

References.

- 1 Review: Kniess T, Laube M, Brust P, Steinbach J. 2-[¹⁸F]Fluoroethyl tosylate – a versatile tool for building ¹⁸F-based radiotracers for positron emission tomography. *Med Chem Commun* 2015;6:1714-1754.
- 2 Cai L, Chin FT, Pike VW, Toyama H, Liow J-S, Zoghbi SS, Modell K, Briard E, Shetty HU, Sinclair K, Donohue S, Tipre D, Kung MP, Dagostin C, Widdowson DA, Green M, Gao W, Herman MM, Ichise M, Innis RB. Synthesis and Evaluation of Two ¹⁸F-Labeled 6-Iodo-2-(4'-*N,N*-dimethylamino)phenylimidazo[1,2-*a*]pyridine Derivatives as Prospective Radioligands for β -Amyloid in Alzheimer's Disease. *J Med Chem* 2004;47: 2208-2218.
- 3 Kämäräinen EL, Kyllönen T, Airaksinen A, Lundkvist C, Yu M, Nägren K, Sandell J, Langer O, Vepsäläinen J, Hiltunen, J, Bergström K, Lötjönen S, Jaakkola T, Halldin C. Preparation of [¹⁸F] β -CFT-FP and [¹¹C] β -CFT-FP, selective radioligands for visualisation of the dopamine transporter using positron emission tomography (PET). *J. Labelled Compd Radiopharm* 2000;43:1235-1244.
- 4 Koivula T, Perhola O, Kämäräinen E-L, Lipponen T, Vepsäläinen J, Solin O. Simplified synthesis of *N*-(3-[¹⁸F]fluoropropyl)-2 β -carbomethoxy-3 β -(4-fluorophenyl)nortropine ([¹⁸F] β -CFT-FP) using [¹⁸F]fluoropropyl tosylate as the labelling reagent. *J Labelled Compd Radiopharm* 2005;48:463-471.
- 5 Chesis PL, Hwang DR, Welch MJ. *N*-(3-[¹⁸F]Fluoropropyl)-*N*-nordiprenorphine: synthesis and characterization of a new agent for imaging opioid receptors with positron emission tomography. *J Med Chem* 1990;33:1482-1490.
- 6 Klok RP, Klein PJ, Herscheid JDM, Windhorst AD. Synthesis of *N*-(3-[¹⁸F]fluoropropyl)-2 β -carbomethoxy-3 β -(4-iodophenyl)nortropine ([¹⁸F]FP- β -CIT). *J. Labelled Compd. Radiopharm.* 2006;49:77-89.
- 7 Erlandsson M, Karimi F, Lindhe Ö, Långström B. ¹⁸F-Labeled metomidate analogues as adrenocortical imaging agents. *Nucl Med Biol* 2009;36:435-445.
- 8 Collier TL, O'Brian JC, Waterhouse RN. Synthesis of [¹⁸F]-1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)-piperidine: a potential sigma-1 receptor radioligand for PET. *J Labelled Compd Radiopharm* 1996;38: 785-794.
- 9 Yamamoto F, Oka H, Antoku S, Ichiya Y, Masuda K, Maeda M. Synthesis and characterization of lipophilic 1-[¹⁸F]fluoroalkyl-2-nitroimidazoles for imaging hypoxia. *Biol Pharm Bull* 1999;22:590-597.
- 10 Maeda M, Sasaki S, Fukumura T, Fukuzawa E, Watanabe K, Kojima M, Tahara T, Masuda K, Ichiya Y. Positron-emitting *N*-[¹⁸F]fluoroalkyl and [¹⁸F]fluoropyrrolidiny analogues of eticlopride as potential in vivo radioligands for dopamine D2 receptors. *Chem Pharm Bull* 1992;40:1793-1798.
- 11 Yamamoto F, Aoki M, Furusawa Y, Ando K, Kuwabara Y, Masuda K, Sasaki S, Maeda M. Synthesis and evaluation of 4-bromo-1-(3-[¹⁸F]fluoropropyl)-2-nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent. *Biol Pharm Bull* 2002;25:616-621.
- 12 Holschbach MH, Olsson RA, Bier D, Wutz W, Sihver W, Schüller M, Palm B, Coenen HH. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[¹⁸F]fluoropropyl)-1-propylxanthine ([¹⁸F]CPFPX): a potent and selective α 1-adenosine receptor antagonist for in vivo imaging. *J Med Chem* 2002;45: 5150-5156.
- 13 Schirmacher R, Mathiasch B, Schirmacher E, Radnic D, Rösch F. Syntheses of novel *N*-([¹⁸F]fluoroalkyl)-*N*-nitroso-4-methyl-benzenesulfonamides and decomposition studies of corresponding ¹⁹F- and bromo-analogues: potential new compounds for the ¹⁸F-labelling of radiopharmaceuticals. *J Labelled Compd Radiopharm* 2003;46:959-977.
- 14 Dumont F, Sultana A, Balter A, Waterhouse RN. Synthesis of [¹⁸F]3-[1-(3-fluoropropyl)-(S)-pyrrolidin-2-ylmethoxy]pyridine ([¹⁸F]NicFP): a potential α 2 β 2 nicotinic acetylcholine receptor radioligand for PET. *J Labelled Compd Radiopharm* 2003;46:1261-1268.
- 15 Kim DW, Ahn D-S, Oh YH, Lee S, Kil HS, Oh SJ, Lee SJ, Kim JS, Ryu JS, Moon DH, Chi DY. A New class of S_N2 reactions catalyzed by protic solvents: facile fluorination for isotopic labeling of diagnostic molecules. *J Am Chem Soc* 2006;128:16394-16397.
- 16 Moore JA, Ayers RS. *The Chemistry of Heterocyclic Compounds*. Vol. 42, New York, John Wiley & Sons; 1983. pp 1-218.
- 17 Médoc M, Sobrio F. Nucleophilic Fluorination and Radiofluorination via Aziridinium Intermediates: N-Substituent Influence, Unexpected Regioselectivity, and Differences between Fluorine-19 and Fluorine-18. *J Org Chem* 2015;80:10086-10097.
- 18 Chi DY, Kilbourn, MR, Katzenellenbogen JA, Welch MJ. A rapid and efficient method for the fluoroalkylation of amines and amides. Development of a method suitable for incorporation of the short-lived positron emitting radionuclide fluorine-18. *J Org Chem* 1987;52:658-664.
- 19 Roehn U, Becaud J, Mu L, Srinivasan A, Stellfeld T, Fitzner A, Graham K, Dinkelborg L, Schubiger AP, Ametamey SM. Nucleophilic ring-opening of activated aziridines: A one-step method for labeling biomolecules with fluorine-18. *J Fluorine Chem* 2009;130:902-912.
- 20 Couty F, David O, Drouillat B. Opening of azetidinium ions with C-nucleophiles. *Tetrahedron Lett* 2007;48:9180-9184.

- 21 Cospito G, Illuminati G, Lillocci C, Petride H. Ring-opening reactions. 3. Mechanistic path vs. ring-strain control in elimination and substitution reactions of 1,1-dimethyl cyclic ammonium ions and their α,α' -dimethyl-substituted derivatives. *J Org Chem* 1981;46: 2944-2947.
- 22 Owens AH, Goehring RR, Lampe JW, Erhardt PW, Lumma Jr WC, Wiggins J. Cardiotoxic agents. 4. Dimaprit analogues as potential cardiovascular selective H₂-agonists. *Eur J Med Chem* 1988;23:295-300.
- 23 Kiesewetter DO, Eckelman WC. Utility of azetidinium methanesulfonates for radiosynthesis of 3-[¹⁸F]fluoropropyl amines. *J Labelled Compd Radiopharm* 2004;47:953-969.
- 24 Grosse-Gehling P, Wuest FR, Peppel T, Köckerling M, Mamat C. 1-(3-[¹⁸F]fluoropropyl)piperazines as model compounds for the radiofluorination of pyrido[2,3-*d*]pyrimidines. *Radiochim Acta* 2011;99:365-373.
- 25 Pretze M, Mamat C. Automated preparation of [¹⁸F]AFP and [¹⁸F]BFP: Two novel bifunctional ¹⁸F-labeling building blocks for Huisgen-click. *J Fluorine Chem* 2013;150:25-35.
- 26 Mosch B, Reissenweber B, Neuber C, Pietzsch J. Eph Receptors and Ephrin Ligands: Important Players in Angiogenesis and Tumor Angiogenesis. *J Oncol* 2010, Article ID: 135285, DOI: 10.1155/2010/135285.
- 27 Wang B. Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: tales of unwitting partners. *Sci Signal* 2011;4:pe28.
- 28 Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. *Am J Pathol* 2006;169:279-293.
- 29 Berclaz G, Flutsch B, Altermatt HJ, Rohrbach V, Djonov V, Ziemiecki A, Dreher E, Andres A-C. Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. *Oncol Rep* 2002;9:985-989.
- 30 Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz Jr S, Arango D. EPHB4 and survival of colorectal cancer patients. *Cancer Res* 2006;66:8943-8948.
- 31 Huang X, Yamada Y, Kidoya H, Naito H, Nagahama Y, Kong L, Katoh SY, Li WL, Ueno M, Takakura N. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis. *Cancer Res* 2007;67:9800-9808.
- 32 Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. *J Biol Chem* 2002;277:46974-46979.
- 33 Chrencik JE, Brooun A, Recht MI, Nicola G, Davis LK, Abagyan R, Widmer H, Pasquale EB, Kuhn P. Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. *J Biol Chem* 2007;282:36505-36513.
- 34 Miyazaki Y, Nakano M, Sato H, Truesdale AT, Stuart JD, Nartey EN, Hightower KE, Kane-Carson L. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-*c*]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases. *Bioorg Med Chem Lett* 2007;17:250-254.
- 35 Choi Y, Syeda F, Walker JR, Finerty Jr PJ, Cuerrier D, Wojciechowski A, Liu Q, Dhe-Paganon S, Gray NS. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. *Bioorg Med Chem Lett* 2009;19:4467-4470.
- 36 Caligiuri M, Molz L, Liu Q, Kaplan F, Xu JP, Majeti JZ, Ramos-Kelsey R, Murthi K, Lievens S, Tavernier J, Kley N. MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells. *Chem Biol* 2006;13:711-722.
- 37 Xiong C, Huang M, Zhang R, Song S, Lu W, Flores II L, Gelovani J, Li C. In vivo small-animal PET/CT of EphB4 receptors using ⁶⁴Cu-labeled peptide. *J Nucl Med* 2011;52:241-248.
- 38 Zhang R, Xiong C, Huang M, Zhou M, Huang Q, Wen X, Liang D, Li C. Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. *Biomaterials* 2011;32:5872-5879.
- 39 Pretze M, Mosch B, Bergmann R, Steinbach J, Pietzsch J, Mamat C. Radiofluorination and first radiopharmacological characterization of a SWLAY peptide based ligand targeting EphA2. *J Labelled Compd Radiopharm* 2014;57:660-665.
- 40 Bardelle C, Cross D, Davenport S, Kettle JG, Ko EJ, Leach AG, Mortlock A, Read J, Roberts NJ, Robins P, Williams EJ. Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilino-pyrimidines. *Bioorg Med Chem Lett* 2008;18:2776-2780.
- 41 Bardelle C, Coleman T, Cross D, Davenport S, Kettle JG, Ko EJ, Leach AG, Mortlock A, Read J, Roberts NJ, Robins P, Williams EJ. Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilino-pyrimidines. *Bioorg Med Chem Lett* 2008;18:5717-5721.
- 42 Bardelle C, Barlaam B, Brooks N, Coleman T, Cross D, Ducray R, Green I, Lambert-van der Brempt C, Olivier A, Read J. Inhibitors of the tyrosine kinase EphB4. Part 3: Identification of non-benzodioxole-based kinase inhibitors. *Bioorg Med Chem Lett* 2010;20:6242-6245.

43 Barlaam B, Ducray R, Lambert-van der Brempt C, Plé P, Bardelle C, Brooks N, Coleman T, Cross D, Kettle JG, Read J. Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series. *Bioorg Med Chem Lett* 2011;21:2207-2211.

44 Mamat C, Mosch B, Neuber C, Köckerling M, Bergmann R, Pietzsch J. Fluorine-18 Radiolabeling and Radiopharmacological Characterization of a Benzodioxolypyrimidine-based Radiotracer Targeting the Receptor Tyrosine Kinase EphB4. *ChemMedChem* 2012;7:1991-2003.

45 Ebert K, Wiemer J, Caballero J, Köckerling M, Steinbach J, Pietzsch J, Mamat C. Development of indazolypyrimidine derivatives as high-affine EphB4 receptor ligands and potential PET radiotracers. *Bioorg Med Chem* 2015;23:6025-6035.

46 OECD Guidelines for the Testing of Chemicals, Section 1. Physical-Chemical properties. Test No. 117: Partition Coefficient (*n*-octanol/water), HPLC Method. <http://dx.doi.org/10.1787/9789264069824-en>.

47 Calculations were made by ChemDraw 16 according to: Ghose AK, Crippen GM. Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. *J Chem Inf Comput Sci* 1987;27:21-35.

48 Calculations were made by ChemDraw 16 according to: Viswanadhan VN, Ghose AK, Revankar GR, Robins RK. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. *J Chem Inf Comput Sci* 1989;29:163-172.

Accepted Article